These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 1686913)

  • 1. The plasma kinetics of digoxin-specific Fab fragments and digoxin in the rabbit.
    Timsina MP; Hewick DS
    J Pharm Pharmacol; 1991 Nov; 43(11):807-10. PubMed ID: 1686913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The plasma disposition and renal elimination of digoxin-specific Fab fragments and digoxin in the rabbit.
    Timsina MP; Hewick DS
    J Pharm Pharmacol; 1992 Oct; 44(10):796-800. PubMed ID: 1360503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time- and dose-dependent digoxin redistribution by digoxin-specific antigen binding fragments in a rat model.
    Renard C; Weinling E; Pau B; Scherrmann JM
    Toxicology; 1999 Sep; 137(2):117-27. PubMed ID: 10521148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of an enzyme-linked immunosorbent assay to study the disposition of sheep digoxin-specific immunoglobulin G and Fab fragments in the rat.
    Johnston PC; Stevenson IH; Hewick DS
    Clin Exp Immunol; 1988 Dec; 74(3):489-93. PubMed ID: 3233793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Digoxin-specific Fab fragments impair renal function in the rat.
    Moran RJ; Struthers AD; Hewick DS
    J Pharm Pharmacol; 1994 Oct; 46(10):854-6. PubMed ID: 7699576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of enzyme-linked immunosorbent assays to study the plasma disposition of sheep polyclonal and rat monoclonal digoxin-specific Fab fragments in the rabbit.
    Timsina MP; Hewick DS
    J Pharm Pharmacol; 1990 Aug; 42(8):572-6. PubMed ID: 1981586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and kinetics of distribution and elimination of sheep digoxin-specific IgG and Fab fragments in the rabbit and baboon.
    Smith TW; Lloyd BL; Spicer N; Haber E
    Clin Exp Immunol; 1979 Jun; 36(3):384-96. PubMed ID: 114346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Digoxin-specific antibody fragments in the treatment of digoxin toxicity.
    Chan BS; Buckley NA
    Clin Toxicol (Phila); 2014; 52(8):824-36. PubMed ID: 25089630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal of advanced digitoxin toxicity and modification of pharmacokinetics by specific antibodies and Fab fragments.
    Ochs HR; Smith TW
    J Clin Invest; 1977 Dec; 60(6):1303-13. PubMed ID: 914999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetics of digoxin and anti-digoxin antibody fragments during treatment of digoxin toxicity.
    Sinclair AJ; Hewick DS; Johnston PC; Stevenson IH; Lemon M
    Br J Clin Pharmacol; 1989 Sep; 28(3):352-6. PubMed ID: 2789929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic aspects of digoxin-specific Fab therapy in the management of digitalis toxicity.
    Ujhelyi MR; Robert S
    Clin Pharmacokinet; 1995 Jun; 28(6):483-93. PubMed ID: 7656506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Digoxin elimination in a functionally anephric patient after digoxin-specific Fab fragment therapy.
    Nuwayhid NF; Johnson GF
    Ther Drug Monit; 1989 Nov; 11(6):680-5. PubMed ID: 2595749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a sensitive radioimmunoassay for Fab fragments: application to Fab pharmacokinetics in humans.
    Thanh-Barthet CV; Urtizberea M; Sabouraud AE; Cano NJ; Scherrmann JM
    Pharm Res; 1993 May; 10(5):692-6. PubMed ID: 8321833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Digoxin-Specific Antibody Fragment Dosing: A Case Series.
    Chhabra N; Valento M; Bryant SM; Aks SE
    Am J Ther; 2016; 23(6):e1597-e1601. PubMed ID: 26057142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of digoxin-specific antibody fragments on digoxin disposition in the rat.
    Johnston PC; Stevenson IH; Hewick DS
    Biochem Pharmacol; 1987 Jul; 36(13):2215-20. PubMed ID: 3606637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal tolerance of digoxin-specific Fab fragments in the rat.
    Advenier E; Mouajjah S; Bazin-Redureau M; Launay JM; Scherrmann JM
    Toxicology; 1998 Apr; 126(3):223-9. PubMed ID: 9674970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interspecies scaling of clearance and volume of distribution for digoxin-specific Fab.
    Grene-Lerouge NA; Bazin-Redureau MI; Debray M; Scherrmann JM
    Toxicol Appl Pharmacol; 1996 May; 138(1):84-9. PubMed ID: 8658517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma exchange for the removal of digoxin-specific antibody fragments in renal failure: timing is important for maximizing clearance.
    Zdunek M; Mitra A; Mokrzycki MH
    Am J Kidney Dis; 2000 Jul; 36(1):177-83. PubMed ID: 10873888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and pharmacokinetic profiles of digoxin immune Fab in four patients with renal impairment.
    Allen NM; Dunham GD; Sailstad JM; Findlay JW
    DICP; 1991 Dec; 25(12):1315-20. PubMed ID: 1815424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The plasma disposition of sheep antibody (Fab) fragments in the guinea-pig and rabbit.
    Timsina MP; Ostenfeld T; Hewick DS
    J Pharm Pharmacol; 1989 Nov; 41(11):786-8. PubMed ID: 2576050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.